Evidence review · from the 250-topic plan
503A vs 503B, decoded: the two kinds of compounding pharmacy and what each means at your checkout
Two legal species compound medications in America. 503A pharmacies compound per patient, per prescription — traditional pharmacies under primarily state-board oversight, following USP quality standards, forbidden from bulk manufacturing. 503B outsourcing facilities register with FDA, follow federal manufacturing-grade standards (CGMP), submit to FDA inspection, and may produce larger batches including office stock. Post-shortage, the compounded GLP-1 world runs overwhelmingly through 503A patient-specific prescriptions — which is why “which pharmacy, and which kind?” is a two-part question every buyer should ask and every honest program should answer. The myth to retire first: neither designation makes a compounded product FDA-approved — 503B's federal oversight covers how it's made, not approval of the product. What each species means for you, how to verify either in minutes, and where this site's own open files sit — below.
503A, plainly
The traditional model: a licensed pharmacy compounds a preparation for you, against your prescription, one patient at a time. Oversight runs primarily through state boards of pharmacy; quality runs through USP chapters (the sterile-compounding standards this market's verification guide teaches you to ask about); and the model's legal core — no compounding without a patient-specific prescription in the post-shortage era — is exactly what makes it the class's dominant lane now. Strengths: personalization is the design, and the state-board license is checkable by anyone in two minutes. Honest limits: standards enforcement varies by state, batch scale is small by law, and the buyer's verification burden is real — which is why the pharmacy's identity is the whole game: an unnamed 503A is an unverifiable one.
503B, plainly
Created by federal law after a national compounding tragedy, outsourcing facilities are a hybrid species: registered with FDA, inspected by FDA, held to CGMP — the manufacturing-grade quality system brand drugmakers follow — and permitted to compound larger batches, including stock for clinics, without per-patient prescriptions at the production step. Strengths: the quality floor is federal and inspected, with published inspection records anyone can search. Honest limits, stated twice because marketing blurs it: CGMP oversight is not product approval — a 503B-compounded GLP-1 is still a compounded, non-FDA-approved product whose trial certificates stay with the brand — and 503B supply in this class has its own regulatory currents (the April 2026 FDA proposal, comments closed, no final rule) that keep the landscape moving.
The post-shortage landscape
During the shortage years, flexibilities let compounders fill the supply gap at scale; with the shortages declared resolved (tirzepatide December 2024, semaglutide early 2025), the lane narrowed to its permanent shape: patient-specific 503A compounding as the default, prescriptions written one at a time, and the bulk-production question living inside the still-unfinished federal rulemaking. For buyers, the practical translation is a filter: a program vague about its pharmacy's name, state licensure, or classification isn't offering mystery — it's failing check three of the five-check screen.
What it means at your checkout
Three buyer questions, and what answers signal. “Which pharmacy compounds my medication?” — a name is table stakes; a shrug ends the evaluation. “503A or 503B?” — either can be legitimate; the willingness to answer is the signal, and the answer sets your verification path (state board vs FDA registry). “What quality documentation exists?” — licensure, USP compliance posture, testing practices; programs proud of their pharmacy volunteer this. Where this site's own files sit, said plainly: the audited anchor's pharmacy identity and classification remain posted open items on the NexLife file — asked, pending, and tracked — because per the data label, an open file named beats a blank smoothed over, and the 9.5 rating holds the missing half-point hostage until it closes. That's not a footnote; it's the standard working in public. The file, opens and all ↗
Verifying either, fast
503A path: state board of pharmacy license lookup (name + state, two minutes), then the USP-practices question in chat, saved. 503B path: FDA's outsourcing-facility registry and inspection database (public, searchable), then the same documentation ask. Both paths end identically: the verification guide's full walk, and the standing rule that provenance questions answered slowly are answered. Neither path ends at “FDA-approved” — that word belongs to the brand lane, priced and argued elsewhere.
FAQ
What's the difference between a 503A and 503B pharmacy?
503A pharmacies compound per-patient prescriptions under state-board oversight and USP standards; 503B outsourcing facilities register with FDA, follow CGMP, face FDA inspection, and may compound larger batches — neither makes the product FDA-approved.
Which type compounds most GLP-1s now?
Post-shortage, the lane runs overwhelmingly through 503A patient-specific prescriptions, with bulk-production questions living in unfinished federal rulemaking.
Is a 503B-compounded GLP-1 FDA-approved?
No — federal CGMP oversight governs how it's made, not product approval; trial certificates stay with the brands.
What should I ask a provider about its pharmacy?
Its name, its 503A/503B classification, and its quality documentation — then verify via state board or FDA registry; refusal to answer is itself the answer.
Sources
- Federal compounding framework (sections 503A/503B); USP sterile-compounding chapters; FDA outsourcing-facility registry.
- Shortage-resolution timeline; April 2026 proposal status.
- Companion files: pharmacy verification, the five-check screen, the data label.